BACKGROUND: Chronic graft-versus-host disease (cGVHD) is the commonest complication of allogeneic bone marrow and blood stem-cell transplantation, occurring in 50% of all cases and causing late mortality in as many as 25%. There are now about 10 000 patients with cGVHD in Germany, and their number is growing by about 500 each year. cGVHD is a chronic multisystem disease due to impaired tolerance mechanisms. It affects many organs in variable ways, impairing organ function and lowering quality of life. METHODS: We present consensus recommendations on the treatment of cGVHD that were developed jointly by the German Working Group on Bone Marrow and Blood Stem-Cell Transplantation, the German and Austrian Societies of Hematology and Oncology, the Swiss Blood Stem-Cell Transplantation Group, and the German-Austrian Working Group on Pediatric Stem-Cell Transplantation. All of the recommendations are based on an evaluation of selected publications. RESULTS: Recommendations are given regarding the diagnostic evaluation of cGVHD, first-line treatment (which has a response rate of 30% to 50%), second-line treatment, and topical immunosuppression. Patients with cGVHD should also receive supportive care including anti-infective prophylaxis, vaccinations, hormone replacement, prevention and treatment of osteoporosis, physiotherapy, rehabilitation, and psychosocial assistance. CONCLUSION: Patients with cGVHD need multidisciplinary care under the guidance of the transplantation center. The aim of these recommendations is to standardize the treatment of cGVHD and thereby improve patient care.
BACKGROUND: Chronic graft-versus-host disease (cGVHD) is the commonest complication of allogeneic bone marrow and blood stem-cell transplantation, occurring in 50% of all cases and causing late mortality in as many as 25%. There are now about 10 000 patients with cGVHD in Germany, and their number is growing by about 500 each year. cGVHD is a chronic multisystem disease due to impaired tolerance mechanisms. It affects many organs in variable ways, impairing organ function and lowering quality of life. METHODS: We present consensus recommendations on the treatment of cGVHD that were developed jointly by the German Working Group on Bone Marrow and Blood Stem-Cell Transplantation, the German and Austrian Societies of Hematology and Oncology, the Swiss Blood Stem-Cell Transplantation Group, and the German-Austrian Working Group on Pediatric Stem-Cell Transplantation. All of the recommendations are based on an evaluation of selected publications. RESULTS: Recommendations are given regarding the diagnostic evaluation of cGVHD, first-line treatment (which has a response rate of 30% to 50%), second-line treatment, and topical immunosuppression. Patients with cGVHD should also receive supportive care including anti-infective prophylaxis, vaccinations, hormone replacement, prevention and treatment of osteoporosis, physiotherapy, rehabilitation, and psychosocial assistance. CONCLUSION:Patients with cGVHD need multidisciplinary care under the guidance of the transplantation center. The aim of these recommendations is to standardize the treatment of cGVHD and thereby improve patient care.
Authors: A Gratwohl; H Baldomero; A Schwendener; M Gratwohl; J Apperley; K Frauendorfer; D Niederwieser Journal: Bone Marrow Transplant Date: 2010-03-29 Impact factor: 5.483
Authors: Tina Dietrich-Ntoukas; Claus Cursiefen; Henrike Westekemper; Philipp Eberwein; Thomas Reinhard; Hartmut Bertz; Johannes Nepp; Anita Lawitschka; Arnd Heiligenhaus; Berthold Seitz; Elisabeth M Messmer; Tobias Meyer-ter-Vehn; Nadezda Basara; Hildegard Greinix; Manuel B Datiles; Stephanie J Lee; Steven Z Pavletic; Daniel Wolff Journal: Cornea Date: 2012-03 Impact factor: 2.651
Authors: C Marks; M Stadler; P Häusermann; D Wolff; S Buchholz; G Stary; S Lee; A Lawitschka; H Bertz Journal: Br J Dermatol Date: 2011-05-26 Impact factor: 9.302
Authors: Daniel Wolff; Armin Gerbitz; Francis Ayuk; Alexander Kiani; Gerhard C Hildebrandt; Georgia B Vogelsang; Sharon Elad; Anita Lawitschka; Gerard Socie; Steven Z Pavletic; Ernst Holler; Hildegard Greinix Journal: Biol Blood Marrow Transplant Date: 2010-06-25 Impact factor: 5.742
Authors: Hildegard T Greinix; Christoph Loddenkemper; Steven Z Pavletic; Ernst Holler; Gerard Socié; Anita Lawitschka; Joerg Halter; Daniel Wolff Journal: Biol Blood Marrow Transplant Date: 2010-08-05 Impact factor: 5.742
Authors: C Blecha; D Wolff; O Kölbl; E Huber; H Helbig; B Holler; E Holler; T Dietrich-Ntoukas Journal: Bone Marrow Transplant Date: 2014-04-28 Impact factor: 5.483
Authors: Nicole L Stout; Daniel Santa Mina; Kathleen D Lyons; Karen Robb; Julie K Silver Journal: CA Cancer J Clin Date: 2020-10-27 Impact factor: 508.702